Intermittent Fasting Monitoring for Human Optimization Utilizing Wearable Technology: an N-of-1 Prospective Study
Trial ID: NCT06630637
Status: COMPLETED
Study type: INTERVENTIONAL
Phase: NA
Start date: 2024-10-07
Completion date: 2025-07-02
Sponsor: Institute for Digital Medicine (WisDM)
Conditions: Intermittent Fasting; Healthy; Digital Health
Interventions: Glucose-Ketone Index (GKI) monitoring; Continuous Glucose Monitoring (CGM); Digital dynamometer; Wearables; Blood tests; Stool tests; Saliva tests; Fitness intervention; Cold & heat intervention; Airofit; 18h fasting; 48h fasting; Three meal phase; Mediterranean-inspired diet; Supplements; Generative AI; Interviews
Locations: The Institute for Digital Medicine (WisDM)
Countries: Singapore
Enrollment: 1
Age range: 21 Years - None
Sex: MALE

Summary:
There is a growing interest in personalized health strategies, including diet, exercise, and fasting regimens, to enhance metabolic fitness. Recent research indicates that intermittent fasting (IF) is useful not only for weight management, but also for energy production and improvement of metabolic well-being.

IF can potentially reduce systemic inflammation and help to prevent chronic diseases. IF research can also help athletes sustain performance during fasting periods. This prospective study aims to investigate the effects of a human optimization program on an individual\&#39;s metabolic health and overall well-being.

This research examines the correlations between continuous glucose monitoring, ketone measurement, exercise routines, heat/cold interventions, diet, supplements and intermittent fasting patterns. The study involves a single participant -the principal investigator- who will adhere to a personalized regimen involving wearable monitoring of metabolic changes, training and intermittent fasting. This research seeks to understand the potential relationships between these factors, contributing to the emerging knowledge on individualized health optimization.

Eligibility criteria:
Inclusion Criteria:

* The principal investigator is the sole participant in this N-of-1 trial: a healthy individual with no chronic diseases or conditions affecting metabolic health.

Exclusion Criteria:

* The principal investigator is the sole participant in this N-of-1 trial.

Outcomes:
Metabolic biomarker analysis: total cholesterol levels; Metabolic biomarker analysis: low density lipoprotein (LDL) cholesterol levels; Metabolic biomarker analysis: high density lipoprotein (HDL) cholesterol levels; Metabolic biomarker analysis: triglycerides levels; Metabolic biomarker analysis: apolipoprotein B (ApoB) levels; Metabolic biomarker analysis: apolipoprotein A1 (ApoA1) levels; Metabolic biomarker analysis: C reactive protein (CRP) levels; Metabolic biomarker analysis: interleukin 1β (IL- 1β) levels; Metabolic biomarker analysis: interleukin 6 (IL- 6) levels; Metabolic biomarker analysis: interleukin 8 (IL- 8) levels; Metabolic biomarker analysis: interleukin 10 (IL- 10) levels; Metabolic biomarker analysis: interleukin 12 (IL- 12) levels; Metabolic biomarker analysis: interleukin 17 (IL- 17) levels; Metabolic biomarker analysis: omega 3:6 ratio; Metabolic biomarker analysis: Microtubule-associated protein 1A/1B-light chain 3 (LC3) levels; Metabolic biomarker analysis: Sequestosome 1 (p62/SQSTM1) levels; Metabolic biomarker analysis: Beclin-1 levels; Metabolic biomarker analysis: Red Blood Cells (RBCs); Metabolic biomarker analysis: White Blood Cells (WBCs); Metabolic biomarker analysis: Hemoglobin (Hb); Metabolic biomarker analysis: Hematocrit (Hct); Metabolic biomarker analysis: Platelets (PLT); Metabolic biomarker analysis: Blood Urea Nitrogen (BUN); Metabolic biomarker analysis: Creatinine; Metabolic biomarker analysis: Estimated Glomerular Filtration Rate (eGFR); Metabolic biomarker analysis: Sodium; Metabolic biomarker analysis: Potassium; Metabolic biomarker analysis: Chloride; Metabolic biomarker analysis: Alanine Aminotransferase (ALT); Metabolic biomarker analysis: Aspartate Aminotransferase (AST); Metabolic biomarker analysis: Alkaline Phosphatase (ALP); Metabolic biomarker analysis: Total Bilirubin; Metabolic biomarker analysis: Albumin; Microbial diversity; Taxonomic abundance; Concentrations of metabolites; Glycemic and ketone monitoring for adherence assessment; Wearable health metrics analysis for physiological monitoring; Artificial intelligence (AI)-enhanced visual data representation for activity monitoring